###begin article-title 0
###xml 62 66 <span type="species:ncbi:10090">Mice</span>
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
###end article-title 0
###begin p 1
Conceived and designed the experiments: RV VZ DK SL. Performed the experiments: VZ DK KL NP. Analyzed the data: RV VZ DK. Contributed reagents/materials/analysis tools: YH SL. Wrote the paper: RV.
###end p 1
###begin p 2
Current address: Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 109 117 <span type="species:ncbi:9606">patients</span>
A somatic activating mutation (V617F) in the JAK2 tyrosine kinase was recently discovered in the majority of patients with polycythemia vera (PV), and some with essential thrombocythemia (ET) and chronic idiopathic myelofibrosis. However, the role of mutant JAK2 in disease pathogenesis is unclear.
###end p 4
###begin title 5
Methods and Findings
###end title 5
###begin p 6
###xml 13 19 <span type="species:ncbi:10090">murine</span>
###xml 145 150 <span type="species:ncbi:10090">mouse</span>
###xml 513 517 <span type="species:ncbi:10090">mice</span>
###xml 863 867 <span type="species:ncbi:10090">mice</span>
We expressed murine JAK2 WT or V617F via retroviral bone marrow transduction/transplantation in the hematopoietic system of two different inbred mouse strains, Balb/c and C57Bl/6 (B6). In both strains, JAK2 V617F, but not JAK2 WT, induced non-fatal polycythemia characterized by increased hematocrit and hemoglobin, reticulocytosis, splenomegaly, low plasma erythropoietin (Epo), and Epo-independent erythroid colonies. JAK2 V617F also induced leukocytosis and neutrophilia that was much more prominent in Balb/c mice than in B6. Platelet counts were not affected in either strain despite expression of JAK2 V617F in megakaryocytes and markedly prolonged tail bleeding times. The polycythemia tended to resolve after several months, coincident with increased spleen and marrow fibrosis, but was resurrected by transplantation to secondary recipients. Using donor mice with mutations in Lyn, Hck, and Fgr, we demonstrated that the polycythemia was independent of Src kinases. Polycythemia and reticulocytosis responded to treatment with imatinib or a JAK2 inhibitor, but were unresponsive to the Src inhibitor dasatinib.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 258 263 <span type="species:ncbi:9606">human</span>
###xml 801 809 <span type="species:ncbi:9606">patients</span>
These findings demonstrate that JAK2 V617F induces Epo-independent expansion of the erythroid lineage in vivo. The fact that the central erythroid features of PV are recapitulated by expression of JAK2 V617F argues that it is the primary and direct cause of human PV. The lack of thrombocytosis suggests that additional events may be required for JAK2 V617F to cause ET, but qualitative platelet abnormalities induced by JAK2 V617F may contribute to the hemostatic complications of PV. Despite the role of Src kinases in Epo signaling, our studies predict that Src inhibitors will be ineffective for therapy of PV. However, we provide proof-of-principle that a JAK2 inhibitor should have therapeutic effects on the polycythemia, and perhaps myelofibrosis and hemostatic abnormalities, suffered by MPD patients carrying the JAK2 V617F mutation.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 343 346 343 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Dameshek1">[1]</xref>
###xml 348 351 348 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-VanEtten1">[2]</xref>
###xml 577 580 577 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Daley1">[3]</xref>
###xml 691 694 691 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Druker1">[4]</xref>
###xml 489 495 <span type="species:ncbi:10090">murine</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
The myeloproliferative diseases (MPDs) chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and chronic idiopathic myelofibrosis (CIMF) are clonal disorders characterized by overproduction of mature myeloerythroid cells, abnormalities of hemostasis and thrombosis, and tendency to progress to acute leukemia [1], [2]. The cause of CML is the product of the Philadelphia chromosome, the BCR-ABL fusion tyrosine kinase. Retroviral expression of BCR-ABL in murine bone marrow (BM) causes CML-like MPD with overproduction of maturing neutrophils [3], whereas the BCR-ABL kinase inhibitor imatinib induces hematologic and cytogenetic remissions in CML patients [4].
###end p 10
###begin p 11
###xml 218 221 218 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Spivak1">[5]</xref>
###xml 789 792 789 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Prchal1">[6]</xref>
###xml 859 862 859 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Correa1">[7]</xref>
###xml 1091 1094 1091 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Temerinac1">[8]</xref>
###xml 1185 1188 1185 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Moliterno1">[9]</xref>
###xml 1300 1304 1300 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Xu1">[10]</xref>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 904 912 <span type="species:ncbi:9606">patients</span>
###xml 986 994 <span type="species:ncbi:9606">patients</span>
###xml 1085 1088 <span type="species:ncbi:10345?0.9234234234234234|species:ncbi:12205?0.0033783783783783786">PRV</span>
By contrast, the pathogenesis of the other MPDs is less clear. PV is characterized by overproduction of mature erythrocytes, increased hematocrit and red cell mass, and splenomegaly due to extramedullary hematopoiesis [5]. Many PV patients also have increased circulating granulocytes and platelets. PV can be complicated by abnormalities of hemostasis, including platelet dysfunction and bleeding, as well as arterial and venous thrombosis. The disease infrequently evolves to acute myeloid leukemia, while progression to a "spent" phase, characterized by myelofibrosis and normal or low hematocrit, is more common. A hallmark of PV is the presence of endogenous erythroid colonies (EEC), erythroid progenitors that form colonies in vitro in the absence of exogenous erythropoietin (Epo) [6], but demonstrate hypersensitivity to insulin-like growth factor-1 [7]. Biochemical and molecular studies of PV patients have revealed no mutations in the Epo receptor, but granulocytes from PV patients have increased transcripts for the urokinase plasminogen activator receptor family member PRV-1 [8], whereas PV platelets show decreased expression of c-Mpl, the receptor for thrombopoietin [9]. Abnormally increased tyrosine phosphatase activity has also been characterized in erythroid progenitors in PV [10]. However, whether these abnormalities are fundamental to the pathogenesis of PV was unclear.
###end p 11
###begin p 12
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Parganas1">[11]</xref>
###xml 392 396 392 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Ugo1">[12]</xref>
###xml 428 432 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-James1">[13]</xref>
###xml 662 666 662 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-James1">[13]</xref>
###xml 827 831 827 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-James1">[13]</xref>
###xml 943 947 943 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Baxter1">[14]</xref>
###xml 949 953 949 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Levine1">[15]</xref>
###xml 1043 1047 1043 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Kralovics1">[16]</xref>
###xml 1298 1302 1298 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Jones1">[17]</xref>
###xml 1303 1307 1303 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Scott1">[19]</xref>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 653 661 <span type="species:ncbi:9606">patients</span>
###xml 795 801 <span type="species:ncbi:10090">murine</span>
###xml 934 942 <span type="species:ncbi:9606">patients</span>
###xml 1098 1105 <span type="species:ncbi:9606">patient</span>
###xml 1194 1202 <span type="species:ncbi:9606">patients</span>
###xml 1256 1264 <span type="species:ncbi:9606">patients</span>
JAK2 is a member of the Janus family of non-receptor tyrosine kinases, and is required for signaling from the Epo receptor and other type I cytokine receptors [11]. Recently, a somatic mutation in the JAK2 tyrosine kinase was identified in MPD patients. Studies of erythroid progenitors from PV patients demonstrated that Epo-independent erythroid maturation was impaired by a JAK2 inhibitor [12] and by siRNA knockdown of JAK2 [13]. This prompted sequencing of the JAK2 gene, which identified a G to A point mutation, resulting in substitution of phenylalanine for valine at amino acid 617 (V617F) in the JAK2 pseudokinase domain in the majority of PV patients [13]. The JAK2 V617F mutant had constitutive kinase activity in vivo in the absence of Epo stimulation, and retroviral expression in murine BM caused erythrocytosis [13]. The same mutation was independently identified through genomic sequencing of tyrosine kinases in MPD patients [14], [15], and by investigation of loss of heterozygosity involving the JAK2 gene on chromosome 9p [16]. The JAK2 V617F mutation is found in nearly every patient with PV and is present in homozygous form through mitotic recombination in up to 30% of patients. The mutation is also found in 30-60% of ET and CIMF patients, but is rarely found outside MPD [17]-[19].
###end p 12
###begin p 13
###xml 483 487 <span type="species:ncbi:10090">mice</span>
The widespread finding of JAK2 V617F in the non-CML MPDs suggests that it may contribute to the pathogenesis of these diseases. However, it is not clear whether JAK2 V617F can be implicated as the direct and primary cause of PV, ET, or CIMF, nor is the relationship between the different MPDs that share the JAK2 mutation understood. Here, we investigated the role of JAK2 V617F in the pathogenesis of MPD by expression of the mutant kinase in the hematopoietic system of laboratory mice, using retroviral BM transduction and transplantation. Our results suggest that JAK2 V617F is the primary cause of PV, but not of ET. We also used this model system to study the signaling pathways in PV, and assess the response of the disease to kinase inhibitor therapy.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
DNA constructs
###end title 15
###begin p 16
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Pear1">[20]</xref>
###xml 40 46 <span type="species:ncbi:10090">murine</span>
The V617F mutation was generated in the murine JAK2 cDNA using PCR mutagenesis, verified by DNA sequencing, and the JAK2 WT or V617F mutant cDNAs cloned into the MIG R1 vector [20] in the position 5' to the internal ribosome entry site.
###end p 16
###begin title 17
Retroviral BM transduction and transplantation
###end title 17
###begin p 18
###xml 95 98 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">kat</italic>
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Roumiantsev1">[21]</xref>
###xml 355 359 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Roumiantsev1">[21]</xref>
###xml 585 588 585 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 588 591 588 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 591 594 591 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hck</italic>
###xml 594 597 594 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 597 600 597 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fgr</italic>
###xml 600 603 600 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 702 706 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Meng1">[22]</xref>
###xml 807 811 807 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Roumiantsev1">[21]</xref>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
###xml 604 608 <span type="species:ncbi:10090">mice</span>
###xml 717 721 <span type="species:ncbi:10090">mice</span>
Generation and titering of replication-defective ecotropic retroviral stocks was done with the kat packaging system as previously described [21]. Retroviral titers were matched by flow cytometric analysis of GFP expression in transduced fibroblasts and primary BM cells. We performed retroviral BM transduction and transplantation as previously described [21], using donors pretreated with 5-fluorouracil (200 mg/kg) four days before harvest, and transplanting lethally irradiated recipients (900 cGy for Balb/c, 1050 cGy for B6). Balb/c and B6 mice were purchased from Taconic Farms; Lyn-/-Hck-/-Fgr-/- mice (>15 generations backcrossed into a B6 background) were the kind gift of Dr. Clifford Lowell [22]. Diseased mice were analyzed by histopathology and flow cytometric analysis as previously described [21]. Blood counts were determined by analysis of retro-orbital blood samples, anticoagulated with potassium EDTA, on a Hemavet 850 rodent hematology analyzer (Drew Scientific).
###end p 18
###begin title 19
Immunoblot analysis
###end title 19
###begin p 20
###xml 173 177 173 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Roumiantsev1">[21]</xref>
###xml 209 210 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
Lysates were prepared from primary myeloerythroid cell suspensions from BM and spleen by direct boiling, fractionated by SDS-PAGE, and immunoblotted as previously described [21]. Antibodies against JAK2, Bcl-XL, and Src were obtained from Upstate Biotechnology, while antibodies against Gab2 were the kind gift of Haihua Gu (Beth Israel-Deaconess Hospital, Boston). All other antibodies, including anti-phospho-Tyr1007/1008 JAK2, anti-phospho-Tyr416 Src, anti-phospho and anti-pan Stat5, anti-phospho-Gab2, and phospho- and anti-pan ERK were obtained from Cell Signaling Technology.
###end p 20
###begin title 21
Southern blot analysis
###end title 21
###begin p 22
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BglII</italic>
###xml 256 259 256 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GFP</italic>
###xml 279 283 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Roumiantsev1">[21]</xref>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
The number of proviral clones in BM and spleen cells from mice with JAK2 V617F-induced MPD was determined by digesting genomic DNA with BglII, fractionation on agarose gels, transfer to nylon membranes, and hybridization with a radiolabeled probe from the GFP gene, as described [21].
###end p 22
###begin title 23
Analysis of erythrocyte lifespan and mass
###end title 23
###begin p 24
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Friedman1">[23]</xref>
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Friedman1">[23]</xref>
###xml 290 295 <span type="species:ncbi:10090">mouse</span>
###xml 597 601 <span type="species:ncbi:10090">mice</span>
Erythrocyte lifespan was determined by in vivo biotinylation of erythrocytes and serial flow cytometric detection of biotinylated red cells using streptavidin-PE, as described [23]. For red cell mass determination, approximately 0.5 ml of peripheral blood was obtained from a healthy donor mouse and biotinylated in vitro as described [23]. The concentration of erythrocytes was determined by counting on a Hemavet 850 hematology analyzer and the percentage of biotinylated erythrocytes determined by FACS. A defined volume (200-300 microl) was then injected into normal or polycythemic recipient mice, whose peripheral blood was sampled two hours later. The total RBC mass was calculated by the following formula: total RBC mass = (%labeling of donor RBC/100)x(#RBC/microL in donor sample)x(#microL injected)x100/(%labeled RBC in recipient).
###end p 24
###begin title 25
CFU-E and Epo assays
###end title 25
###begin p 26
###xml 117 123 <span type="species:ncbi:10090">murine</span>
###xml 223 228 <span type="species:ncbi:9606">human</span>
BM or spleen cells were plated in methylcellulose (MethoCult M3234, Stem Cell Technologies) with 5 ng/ml recombinant murine IL-3 (Peprotech) as a source of burst-promoting activity and varying concentrations of recombinant human Epo (Ortho). CFU-E colonies were identified on day 3 by morphology and diaminofluorine staining. Plasma Epo levels were determined by ELISA (R&D Systems).
###end p 26
###begin title 27
Tail bleeding time
###end title 27
###begin p 28
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Ramakrishnan1">[24]</xref>
Tail bleeding times were determined as previously described [24]. Briefly, following induction of isoflurane anesthesia, a 5 mm portion of the tail tip was severed by scalpel and the tip immersed in 0.9% saline solution at 37degreesC. The time of cessation of spontaneous bleeding was recorded; if bleeding continued for more than 15 minutes, the time was recorded as 900 seconds, and hemostasis achieved by cauterization of the tail tip.
###end p 28
###begin title 29
Purification of megakaryocytes
###end title 29
###begin p 30
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Drachman1">[25]</xref>
###xml 195 200 <span type="species:ncbi:9606">human</span>
Megakaryocytes were purified after in vitro growth as previously described [25]. Briefly, BM or spleen cells were grown for 72-96 hours in IMDM with 1% Nutridoma (Roche) and 38 ng/ml recombinant human thrombopoietin (Peprotech), and megakaryocytes purified by sedimentation over a discontinuous albumin gradient. The resulting population was >95% megakaryocytes based on morphology and staining for CD41 and acetylcholinesterase.
###end p 30
###begin title 31
Drug treatments
###end title 31
###begin p 32
###xml 241 245 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Wolff1">[26]</xref>
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Shah1">[27]</xref>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 495 499 <span type="species:ncbi:10090">mice</span>
Imatinib (obtained from the pharmacy) and dasatinib (kind gift of Drs. Frank Lee and Roberto Weinmann, Bristol-Myers Squibb) were dissolved in a water:propylene glycol (50:50) vehicle and administered by twice-daily oral gavage at 100 mg/kg [26] and 10 mg/kg [27] per dose, respectively. Control mice received vehicle alone. AG-490 (Calbiochem) was dissolved in 50% DMSO and delivered by subcutaneous osmotic minipump (Alzet model 2002) at a rate of about 300 microg per 24 hours, while control mice received minipumps loaded with 50% DMSO alone.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
JAK2 V617F induces polycythemia through Epo-independent overproduction of erythrocytes
###end title 34
###begin p 35
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Roumiantsev1">[21]</xref>
###xml 440 456 440 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g001">Figure 1A and 1B</xref>
###xml 607 623 607 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g001">Figure 1C and 1D</xref>
###xml 688 697 688 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g001">Figure 1E</xref>
###xml 778 787 778 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g001">Figure 1F</xref>
###xml 1036 1045 1036 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g001">Figure 1G</xref>
###xml 1305 1314 1305 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g001">Figure 1H</xref>
###xml 85 91 <span type="species:ncbi:10090">murine</span>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 1095 1099 <span type="species:ncbi:10090">mice</span>
###xml 1371 1375 <span type="species:ncbi:10090">mice</span>
###xml 1697 1701 <span type="species:ncbi:10090">mice</span>
###xml 1905 1910 <span type="species:ncbi:9606">human</span>
To investigate the molecular pathogenesis of MPD induced by JAK2 V617F, we expressed murine JAK2 WT or JAK2 V617F in BM of two different strains of mice, Balb/c and C57Bl/6 (B6), using retroviral transduction and transplantation [21]. In both strains, recipients of JAK2 V617F-transduced BM exhibited markedly increased blood hematocrit and hemoglobin levels that were evident by three weeks after transplantation and sustained for months (Figure 1A and 1B), while recipients of JAK2 WT- or vector-transduced BM were normal. Polycythemia was accompanied by a striking increase in circulating reticulocytes (Figure 1C and 1D). The erythrocyte lifespan in JAK2 V617F recipients was normal (Figure 1E), and polycythemia was accompanied by a proportional increase in red cell mass (Figure 1F). These results indicate that the polycythemia in these recipients was due to primary overproduction of erythrocytes, not to an increase in red cell survival or decrease in plasma volume. Plasma Epo levels were suppressed in JAK2 V617F recipients (Figure 1G), demonstrating that the erythropoiesis in these mice is autonomous, and not driven by overproduction of Epo. CFU-E from BM or spleen of these recipients showed increased sensitivity to Epo, with about 25-30% of CFU-E growing in the absence of exogenous Epo (Figure 1H), demonstrating the presence of EEC in the polycythemic mice. Interestingly, the frequency of Epo-independent BFU-E in these recipients was much lower (data not shown), suggesting that JAK2 V617F acts in the most differentiated erythroid progenitors to promote Epo-independent maturation. Together, these results indicate that JAK2 V617F expression directly induces polycythemia in mice through Epo-independent overproduction of erythrocytes. The fact that the central erythroid features of PV are recapitulated by expression of JAK2 V617F argues that it is the primary and direct cause of human PV.
###end p 35
###begin title 36
JAK2 V617F induces strain-dependent leukocytosis, but not thrombocytosis
###end title 36
###begin p 37
###xml 222 231 222 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g002">Figure 2A</xref>
###xml 325 341 325 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g002">Figure 2A and 2B</xref>
###xml 477 486 477 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g002">Figure 2B</xref>
###xml 687 696 687 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g002">Figure 2C</xref>
###xml 765 774 765 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g002">Figure 2D</xref>
###xml 899 908 899 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g002">Figure 2E</xref>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
###xml 552 557 <span type="species:ncbi:10090">mouse</span>
In contrast to the polycythemia, the effects of JAK2 V617F expression on leukocyte and platelet counts were more variable. JAK2 V617F induced significant leukocytosis in Balb/c mice, but only a modest increase in B6 mice (Figure 2A). The majority of the leukocytes were mature neutrophils with some immature erythroid cells (Figure 2A and 2B), and there was a notable absence of circulating immature myeloid progenitors that are characteristic of BCR-ABL-induced CML-like MPD (Figure 2B). These results suggest that genetic differences between the two mouse strains affect the leukocytosis induced by JAK2 V617F. JAK2 V617F expression did not affect the platelet count in either strain (Figure 2C), despite evidence of proviral expression of GFP in megakaryocytes (Figure 2D). However, JAK2 V617F recipients had a marked defect in platelet function, with significantly prolonged tail bleeding time (Figure 2E). The lack of thrombocytosis suggests that additional events may be required for JAK2 V617F to cause ET, but qualitative platelet abnormalities induced by JAK2 V617F may contribute to the hemostatic complications of PV.
###end p 37
###begin title 38
Pathological characterization of MPD induced by JAK2 V617F
###end title 38
###begin p 39
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Roumiantsev1">[21]</xref>
###xml 485 486 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 508 509 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 721 730 717 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g003">Figure 3A</xref>
###xml 887 896 883 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g003">Figure 3B</xref>
###xml 969 978 965 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g003">Figure 3C</xref>
###xml 1131 1147 1127 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g003">Figure 3A and 3B</xref>
###xml 1336 1345 1332 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g003">Figure 3D</xref>
###xml 1465 1474 1461 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g003">Figure 3E</xref>
###xml 1650 1654 1646 1650 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/lo</sup>
###xml 1660 1661 1656 1657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1686 1695 1682 1691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g003">Figure 3F</xref>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 379 383 <span type="species:ncbi:10090">mice</span>
###xml 1308 1312 <span type="species:ncbi:10090">mice</span>
Despite the marked polycythemia, the MPD induced by JAK2 V617F was non-fatal in both strains, with recipients surviving for many months. By contrast, BCR-ABL-induced CML-like MPD is rapidly fatal in mice due to massive infiltration of lungs, liver, and spleen with maturing neutrophils [21]. At autopsy, JAK2 V617F recipients had significant splenomegaly, particularly in Balb/c mice (mean spleen weight 0.58+/-0.19 g versus 0.08+/-0.01 for Balb/c recipients of JAK2 WT-transduced BM, P = 0.0023 by unpaired t-test), but no involvement of lymph nodes or thymus, and no pulmonary hemorrhages. The BM of JAK2 V617F recipients was hypercellular, with a predominance of myeloid over erythroid cells, and less than 5% blasts (Figure 3A). Spleens exhibited massively increased erythroid precursors with partial disruption of follicular architecture and infiltration with mature myeloid cells (Figure 3B). Livers showed moderate periportal extramedullary myeloerythropoiesis (Figure 3C), while lungs had only minimal myeloid infiltration (data not shown). There were increased numbers of abnormal megakaryocytes present in BM and spleen (Figure 3A and 3B). When isolated after in vitro culture in thrombopoietin, megakaryocytes from JAK2 V617F recipients were noticeably smaller than their counterparts from normal mice or JAK2 WT recipients (Figure 3D), with many micromegakaryotes undergoing proplatelet formation and mitosis. Flow cytometric analysis of BM and spleen (Figure 3E) demonstrated GFP expression in myeloid, erythroid, megakaryocytic, and lymphoid cells, with a shift in erythropoiesis to the spleen, and a relative increase in immature (CD71+/loTER119+) erythroid progenitors (Figure 3F).
###end p 39
###begin title 40
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Constitutive activation of JAK2 V617F and downstream signaling pathways in polycythemic mice
###end title 40
###begin p 41
###xml 324 333 324 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g004">Figure 4A</xref>
###xml 619 628 619 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g004">Figure 4B</xref>
###xml 927 928 927 928 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 1019 1020 1019 1020 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 1404 1413 1404 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g004">Figure 4C</xref>
###xml 1474 1478 1474 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Roumiantsev1">[21]</xref>
###xml 967 971 <span type="species:ncbi:10090">mice</span>
###xml 1148 1152 <span type="species:ncbi:10090">mice</span>
###xml 1240 1246 <span type="species:ncbi:10090">murine</span>
To determine the biochemical properties of JAK2 V617F in vivo, we performed western blot analysis of extracts from primary myeloerythroid cells from recipients of JAK2 V617F- and JAK2 WT-transduced BM. There was modest (2- to 3-fold) overexpression of JAK2 in both cohorts, relative to the level of endogenous JAK2 protein (Figure 4A). There was constitutive activation of JAK2 V617F in BM and spleen cells, as evidenced by phosphorylation at the activation loop tyrosines 1007 and 1008, whereas JAK2 WT was not detectably phosphorylated. We also analyzed several signaling pathways that are activated by Epo receptor (Figure 4B). There was increased phosphorylation of Gab2 and ERK in spleens and BM from JAK2 V617F recipients that were somewhat variable from sample to sample, but no consistent activation of Akt (data not shown). There was constitutive activation of Stat5 and detectable expression of the Stat5 target Bcl-XL in BM of both normal and polycythemic mice, with increased Stat5 phosphorylation and Bcl-XL in spleens from JAKV617F recipients, although this could in part reflect the increase in splenic myeloerythroid cells in these mice. These results suggest that JAK2 V617F activates several signaling pathways in primary murine hematopoietic cells. Southern blot analysis of proviral integration demonstrated that multiple proviral clones contributed to the MPD induced by JAK2 V617F (Figure 4C), similar to that observed for BCR-ABL-induced CML-like MPD [21].
###end p 41
###begin title 42
Progression of polycythemia to myelofibrosis
###end title 42
###begin p 43
###xml 254 263 254 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g005">Figure 5A</xref>
###xml 458 467 458 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g005">Figure 5B</xref>
###xml 865 874 865 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g005">Figure 5C</xref>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 506 511 <span type="species:ncbi:9606">human</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
The polycythemia induced by JAK2 V617F was maximal at 3 to 4 months post-transplantation, but tended to decrease with time in both strains, with hematocrit and reticulocyte counts returning to nearly normal ranges by 7 to 8 months after transplantation (Figure 5A), and some mice developing overt anemia. This coincided with a gradual but marked increase in fibrosis in the BM and spleen of JAK2 V617F recipients that was not observed in JAK2 WT recipients (Figure 5B). This is reminiscent of evolution of human PV to a "spent phase" resembling CIMF. Interestingly, polycythemia and reticulocytosis were efficiently resurrected in secondary mice by transplantation of BM and/or spleen cells from primary JAK2 V617F recipients, and this was equally true for donors harvested in the early, polycythemic phase of the disease as well as the later, myelofibrotic phase (Figure 5C). These results suggest that JAK2 V617F expression induces myelofibrosis, but the resulting impairment of erythropoiesis is due to a defect of the hematopoietic microenvironment, rather than a deficiency of malignant hematopoietic stem cells.
###end p 43
###begin title 44
JAK2 V617F-induced polycythemia is independent of Src kinases
###end title 44
###begin p 45
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Richmond1">[28]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Ugo1">[12]</xref>
###xml 513 517 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Meng1">[22]</xref>
###xml 519 523 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Hu1">[29]</xref>
###xml 668 672 668 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Ingley1">[30]</xref>
###xml 703 706 703 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 706 709 706 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 709 712 709 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hck</italic>
###xml 712 715 712 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 715 718 715 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fgr</italic>
###xml 718 721 718 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 875 887 875 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g006">Figure 6A&#8211;6C</xref>
###xml 1458 1461 1458 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 1461 1464 1461 1464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1464 1467 1464 1467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hck</italic>
###xml 1467 1470 1467 1470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1470 1473 1470 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fgr</italic>
###xml 1473 1476 1473 1476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1630 1639 1630 1639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g006">Figure 6D</xref>
###xml 299 307 <span type="species:ncbi:9606">patients</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
This model of JAK2 V617F-induced polycythemia can be used to investigate signaling pathways critical for disease pathogenesis. Epo stimulation activates Src family kinases including Lyn [28], while a Src kinase inhibitor impaired the Epo-independent differentiation of erythroid progenitors from PV patients [12]. To investigate the role of Src kinases in the polycythemia induced by JAK2 V617F, we employed donor mice lacking Lyn, Hck, and Fgr, the three principal Src kinases in myeloerythroid progenitor cells [22], [29], as BM donors for transduction with JAK2 V617F. These mice have normal baseline hematopoiesis, but defective erythropoietic responses to stress [30]. Interestingly, recipients of Lyn-/-Hck-/-Fgr-/- BM transduced with JAK2 V617F developed polycythemia and reticulocytosis that tended to be greater than recipients of JAK2 V617F-transduced WT donor BM (Figure 6A-6C), although this did not reach statistical significance. The results demonstrate that these particular Src kinases are not required for polycythemia induced by JAK2 V617F, and might even play a negative role in JAK2 V617F signaling. There is a possibility that one or more of the other six vertebrate Src family kinases might compensate for lack of these three, particularly Fyn, Yes, and c-Src, which are expressed in myeloid cells. However, there was no overexpression of Fyn, Yes, or c-Src in myeloerythroid cells from polycythemic recipients of JAK2 V617F-transduced Lyn-/-Hck-/-Fgr-/- BM, and little or no detectable activation of these Src kinases, as assessed by antibody recognizing the phosphorylated activation loop tyrosine in Src (Figure 6D). This suggests that compensation by other Src family members is unlikely to play a role in polycythemia induced by JAK2 V617F in these mutant cells.
###end p 45
###begin title 46
JAK2 V617F-induced polycythemia responds to kinase inhibitor therapy
###end title 46
###begin p 47
###xml 324 328 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Jones2">[31]</xref>
###xml 572 581 572 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g007">Figure 7A</xref>
###xml 705 706 705 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1036 1040 1036 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Levine1">[15]</xref>
###xml 1042 1046 1042 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Thompson1">[32]</xref>
###xml 1073 1077 1073 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Meydan1">[33]</xref>
###xml 1158 1160 1158 1160 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1198 1207 1194 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g007">Figure 7B</xref>
###xml 1332 1336 1328 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Meydan1">[33]</xref>
###xml 1541 1550 1537 1546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g007">Figure 7C</xref>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 254 259 <span type="species:ncbi:9606">human</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
###xml 639 643 <span type="species:ncbi:10090">mice</span>
###xml 1414 1418 <span type="species:ncbi:10090">mice</span>
We treated cohorts of polycythemic JAK2 V617F recipient mice for a 2-week period with small molecule tyrosine kinase inhibitors, including imatinib and the dual ABL/Src inhibitor dasatinib (BMS-354825). Imatinib therapy can reduce the hematocrit in some human PV patients, but has minimal effects on the level of JAK2 V617F [31]. Relative to vehicle-treated controls, imatinib-treated mice demonstrated significant decreases in hematocrit and reticulocyte counts, while the corresponding responses to dasatinib were less robust and did not reach statistical significance (Figure 7A). Imatinib therapy had no effect on hematocrit in normal mice, and neither drug decreased the percentage of circulating GFP+ leukocytes (data not shown). These results suggest that imatinib impairs JAK2 V617F-induced erythropoiesis through inhibition of a target other than ABL or c-Kit, and confirm that Src kinases may not be good targets for therapy in PV. There are no JAK2 inhibitors in clinical use, but the isoquinolinone compound JAK inhibitor I [15], [32] and the tyrphostin AG-490 [33] both inhibited the proliferation of Ba/F3 cells expressing JAK2 V617F with an IC50 of 0.3 and 3.5 microM, respectively (Figure 7B). AG-490 is not orally bioavailable, and parenteral administration is complicated by its short half-life and low solubility [33]. Nonetheless, continuous parenteral administration of AG-490 to polycythemic mice over a 2-week period caused a modest but significant decrease in hematocrit with a more pronounced drop in reticulocytes (Figure 7C), suggesting that chronic treatment with a JAK2 inhibitor would have therapeutic benefit in PV.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-James1">[13]</xref>
###xml 97 101 97 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Kralovics1">[16]</xref>
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Zhao1">[34]</xref>
###xml 358 362 358 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Campbell1">[35]</xref>
###xml 422 426 422 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-James1">[13]</xref>
###xml 428 432 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Levine1">[15]</xref>
###xml 526 530 526 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-James1">[13]</xref>
###xml 532 536 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Levine1">[15]</xref>
###xml 538 542 538 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Kralovics1">[16]</xref>
###xml 712 716 712 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Lu1">[36]</xref>
###xml 844 848 844 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-James1">[13]</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 308 315 <span type="species:ncbi:9606">patient</span>
###xml 780 786 <span type="species:ncbi:10090">murine</span>
###xml 839 843 <span type="species:ncbi:10090">mice</span>
The JAK2 V617F mutation has been recently identified in most patients with PV, ET, and CIMF [13]-[16], [34]. While the initial frequency of the JAK2 V617F mutation reported in PV patients varied from 65-90%, upon the application of more sensitive sequencing methods, the mutation is detected in nearly every patient meeting rigorous clinical criteria for PV [35]. The mutant kinase has constitutive activity in cell lines [13], [15], and can transform IL-3 dependent hematopoietic cells such as Ba/F3 to cytokine independence [13], [15], [16]. This transformation activity may depend upon co-expression of a single-chain type I cytokine receptor, such as Epo receptor, G-CSF receptor, or thrombopoietin receptor [36]. In the initial report, retroviral expression of JAK2 V617F in murine BM induced erythrocytosis in transplanted recipient mice [13], but the syndrome was not characterized further.
###end p 49
###begin p 50
###xml 325 329 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Wernig1">[37]</xref>
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Lacout1">[38]</xref>
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Cario1">[39]</xref>
###xml 430 434 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-BellanneChantelot1">[40]</xref>
###xml 845 849 845 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Tefferi1">[41]</xref>
###xml 931 935 931 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-James1">[13]</xref>
###xml 112 117 <span type="species:ncbi:9606">human</span>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 570 574 <span type="species:ncbi:10090">mice</span>
###xml 765 773 <span type="species:ncbi:9606">patients</span>
Here, we have demonstrated that JAK2 V617F induces the complete spectrum of the clinicopathological features of human PV in mice, including polycythemia due to overproduction of erythrocytes, increased red cell mass, low plasma Epo levels, and presence of EEC in BM and spleen. Others have recently reported similar findings [37], [38]. Studies of familial PV have shown that the JAK2 V617F mutation is acquired somatically [39], [40], but have suggested that mutation in another gene may precede the JAK2 mutation in PV. However, the facts that polycythemia induced in mice by JAK2 V617F is polyclonal and manifested immediately following engraftment argue that JAK2 V617F is both necessary and sufficient for this phenotype. Increased expression of JAK2 V617F in patients with homozygous mutations may increase severity of the phenotype in PV [41], perhaps because the mutant and WT JAK2 kinases compete for Epo receptor binding [13]. In our model, robust polycythemia is induced by modest overexpression of JAK2 V617F in BM with two normal JAK2 genes, but further studies will be necessary to determine whether the phenotype is influenced by levels of normal JAK2. Taken together, these results establish JAK2 V617F as the direct cause of PV.
###end p 50
###begin p 51
###xml 534 535 534 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 997 1001 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Levine2">[42]</xref>
###xml 1083 1087 1083 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Campbell2">[43]</xref>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 800 808 <span type="species:ncbi:9606">patients</span>
###xml 988 996 <span type="species:ncbi:9606">patients</span>
###xml 1015 1023 <span type="species:ncbi:9606">patients</span>
###xml 1512 1520 <span type="species:ncbi:9606">patients</span>
###xml 1602 1606 <span type="species:ncbi:10090">mice</span>
In contrast to the polycythemia, the effect of JAK2 V617F on the leukocyte and platelet counts was more variable. JAK2 V617F induced striking leukocytosis and neutrophilia in Balb/c mice, but leukocytosis was much milder in B6 recipients. This finding suggests that genetic differences between the two inbred strains modify the leukocyte response to the mutant JAK2 kinase. Somewhat surprisingly, there was no effect of JAK2 V617F on the platelet count in either strain, despite the detection of proviral gene expression (GFP) in CD41+ cells from spleen and BM, and in megakaryocytes purified from short-term in vitro cultures. This suggests that JAK2 V617F does not directly induce an increase in platelets, and that additional mutations or factors are necessary to explain the thrombocytosis in ET patients with JAK2 V617F. This is consistent with clinical studies demonstrating that the allelic ratio of the JAK2 V617F mutation does not account for the clonal hematopoiesis in many ET patients [42], and that ET patients with the JAK2 V617F mutation tend to have PV-like features [43]. Despite the lack of effect on platelet number, JAK2 V617F expression caused profound abnormalities of megakaryocyte maturation and platelet function, manifested by small megakaryocytes, abnormal mitoses during proplatelet formation, and a markedly prolonged tail bleeding time. These findings imply that JAK2 V617F might be the direct cause of the hemostatic abnormalities and mucosal bleeding frequently encountered in PV patients. We did not observe any obvious thrombotic events in our cohorts of polycythemic mice despite the significant elevation in hematocrit, and further studies will be necessary to determine if recipients of JAK2 V617F-transduced BM have abnormalities of coagulation.
###end p 51
###begin p 52
###xml 521 525 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Campbell3">[44]</xref>
###xml 1033 1037 1033 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Westervelt1">[45]</xref>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
###xml 954 958 <span type="species:ncbi:10090">mice</span>
The polycythemia induced by JAK2 V617F was sustained for several months, but eventually hematocrit and reticulocyte counts returned to normal levels in both strains by 8 months after transplantation. This was accompanied by prominent fibrosis in both BM and spleen of these recipients. This process bears a striking resemblance to the "spent" phase of PV, a condition resembling CIMF. CIMF patients with the JAK2 V617F mutation are clinically distinct from those lacking JAK2 mutation, and have a worse overall prognosis [44]. Our findings suggest that some or all CIMF patients with JAK2 V617F might actually represent PV patients that progressed to myelofibrosis prior to diagnosis. It is not clear whether the defective hematopoiesis in spent phase PV and CIMF is due to a deficiency of hematopoietic stem cells, or to a defective hematopoietic microenvironment. The fact that polycythemia can be efficiently transplanted to secondary recipients from mice with myelofibrosis argues that the problem is with the soil, not the seed [45].
###end p 52
###begin p 53
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Richmond1">[28]</xref>
###xml 529 533 529 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-James1">[13]</xref>
###xml 987 991 987 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Shah1">[27]</xref>
###xml 1369 1373 1369 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Jones2">[31]</xref>
###xml 1480 1484 1480 1484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Schittenhelm1">[46]</xref>
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 743 747 <span type="species:ncbi:10090">mice</span>
###xml 941 945 <span type="species:ncbi:10090">mice</span>
###xml 1176 1184 <span type="species:ncbi:9606">patients</span>
###xml 1360 1368 <span type="species:ncbi:9606">patients</span>
###xml 1940 1944 <span type="species:ncbi:10090">mice</span>
###xml 2298 2306 <span type="species:ncbi:9606">patients</span>
This model system of human PV should be valuable for investigating the signaling pathways required for disease pathogenesis, and for testing the response to novel therapies, particularly drugs directed against specific molecular targets. In this report, we investigated the role of Src family kinases in the pathogenesis of JAK2 V617F-induced polycythemia. Although Src kinases are activated by JAK2 in erythroid cells upon Epo stimulation [28] and a Src inhibitor impaired Epo-independent maturation of PV erythroid progenitors [13], we demonstrated that polycythemia induced by JAK2 V617F was independent of Lyn, Hck, and Fgr, the three principal Src family kinases expressed in myeloerythroid cells. In complementary studies where diseased mice were treated with dasatinib, a potent inhibitor of both ABL and Src kinases, there was minimal response of polycythemia and reticulocytosis to a regimen that is very effective for treatment of mice inoculated with BCR-ABL-expressing cells [27]. These studies suggest that other Src family kinases are not compensating for deficiency of Lyn, Hck, and Fgr, and argue that therapy directed at Src kinases will be ineffective in PV patients. By contrast, imatinib therapy did cause a significant decrease in hematocrit and reticulocyte counts in JAK2 V617F recipients, and similar responses have been reported in PV patients [31]. The fact that imatinib was more effective than dasatinib indicates that a target other than ABL or c-Kit [46] mediates these responses. By analogy to CML, if PV is caused directly by JAK2 V617F, then the disease should be exquisitely sensitive to small molecule inhibitors of JAK2. There are no inhibitors of JAK kinases in current clinical use, and existing preclinical JAK2 inhibitors are compromised by lack of oral bioavailability and short in vivo half-life. Nevertheless, continuous parenteral delivery of the tyrphostin JAK2 inhibitor AG-490 to polycythemic mice caused a modest but significant drop in hematocrit, with a more profound decrease in reticulocyte count. These results provide proof-of-principle that more chronic administration of a potent, orally delivered JAK2 inhibitor should have therapeutic effects on the polycythemia, and perhaps the myelofibrosis and hemostatic abnormalities, suffered by MPD patients carrying the JAK2 V617F mutation. Further studies using this model should clarify the molecular pathogenesis of JAK2 V617F-associated MPD, and allow preclinical testing of novel therapies for these diseases.
###end p 53
###begin p 54
We thank Mo-Ying Hsieh and Oya Cingoz for assistance with erythroid colony and Epo assays and Drs. Frank Lee and Roberto Weinmann of Bristol-Myers Squibb for providing dasatinib.
###end p 54
###begin title 55
References
###end title 55
###begin article-title 56
Some speculations on the myeloproliferative disorders.
###end article-title 56
###begin article-title 57
Focus on myeloproliferative diseases and myelodysplastic syndromes.
###end article-title 57
###begin article-title 58
###xml 61 68 61 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bcr/abl</sup>
###xml 61 68 61 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>bcr/abl</sup></italic>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
###end article-title 58
###begin article-title 59
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
###end article-title 59
###begin article-title 60
Polycythemia vera: myths, mechanisms, and management.
###end article-title 60
###begin article-title 61
Letter: Bone-marrow responses in polycythemia vera.
###end article-title 61
###begin article-title 62
Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium.
###end article-title 62
###begin article-title 63
###xml 11 14 <span type="species:ncbi:10345?0.9234234234234234|species:ncbi:12205?0.0033783783783783786">PRV</span>
Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera.
###end article-title 63
###begin article-title 64
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
###end article-title 64
###begin article-title 65
PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells.
###end article-title 65
###begin article-title 66
Jak2 is essential for signaling through a variety of cytokine receptors.
###end article-title 66
###begin article-title 67
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.
###end article-title 67
###begin article-title 68
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
###end article-title 68
###begin article-title 69
###xml 49 54 <span type="species:ncbi:9606">human</span>
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
###end article-title 69
###begin article-title 70
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
###end article-title 70
###begin article-title 71
A gain-of-function mutation of JAK2 in myeloproliferative disorders.
###end article-title 71
###begin article-title 72
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
###end article-title 72
###begin article-title 73
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
###end article-title 73
###begin article-title 74
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.
###end article-title 74
###begin article-title 75
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
###end article-title 75
###begin article-title 76
Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.
###end article-title 76
###begin article-title 77
Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn.
###end article-title 77
###begin article-title 78
###xml 59 65 <span type="species:ncbi:10090">murine</span>
Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant.
###end article-title 78
###begin article-title 79
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Increased thrombin responsiveness in platelets from mice lacking glycoprotein V.
###end article-title 79
###begin article-title 80
###xml 47 53 <span type="species:ncbi:10090">murine</span>
Thrombopoietin signal transduction in purified murine megakaryocytes.
###end article-title 80
###begin article-title 81
###xml 107 113 <span type="species:ncbi:10090">murine</span>
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
###end article-title 81
###begin article-title 82
Overriding imatinib resistance with a novel ABL kinase inhibitor.
###end article-title 82
###begin article-title 83
Turning cells red: signal transduction mediated by erythropoietin.
###end article-title 83
###begin article-title 84
###xml 48 56 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCR-ABL1</italic>
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
###end article-title 84
###begin article-title 85
Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis.
###end article-title 85
###begin article-title 86
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.
###end article-title 86
###begin article-title 87
Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.
###end article-title 87
###begin article-title 88
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.
###end article-title 88
###begin article-title 89
Identification of an acquired JAK2 mutation in polycythemia vera.
###end article-title 89
###begin article-title 90
###xml 56 61 <span type="species:ncbi:9606">human</span>
Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.
###end article-title 90
###begin article-title 91
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
###end article-title 91
###begin article-title 92
###xml 99 105 <span type="species:ncbi:10090">murine</span>
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
###end article-title 92
###begin article-title 93
###xml 24 30 <span type="species:ncbi:10090">murine</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.
###end article-title 93
###begin article-title 94
The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera.
###end article-title 94
###begin article-title 95
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.
###end article-title 95
###begin article-title 96
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
###end article-title 96
###begin article-title 97
###xml 218 226 <span type="species:ncbi:9606">patients</span>
X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis.
###end article-title 97
###begin article-title 98
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
###end article-title 98
###begin article-title 99
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
###end article-title 99
###begin article-title 100
###xml 77 82 <span type="species:ncbi:9606">human</span>
Seed versus soil: the importance of the target cell for transgenic models of human leukemias.
###end article-title 100
###begin article-title 101
###xml 171 176 <span type="species:ncbi:9606">human</span>
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
###end article-title 101
###begin article-title 102
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts.
###end article-title 102
###begin article-title 103
Jak2 is involved in c-Myc induction by Bcr-Abl.
###end article-title 103
###begin title 104
Figures and Tables
###end title 104
###begin title 105
JAK2 V617F induces polycythemia through autonomous overproduction of erythrocytes.
###end title 105
###begin p 106
###xml 181 182 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 236 237 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 214 220 <span type="species:ncbi:10090">murine</span>
(A-C): Hematocrit (A), blood hemoglobin (B), and reticulocyte counts (C) from cohorts of Balb/c or B6 mice transplanted with syngeneic BM cells transduced with empty vector (green, n = 2), or retrovirus expressing murine JAK2 WT (blue, n = 10) or JAK2 V617F (red, n = 15).
###end p 106
###begin p 107
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
In the case of the B6 cohorts, untransplanted mice ("Normal", n = 4) were used instead of empty vector controls.
###end p 107
###begin p 108
###xml 83 84 83 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 189 190 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The difference between JAK2 V617F and JAK2 WT recipients was significant (unpaired t-test) for hematocrit (P<0.0001 for Balb/c and P = 0.0071 for B6), hemoglobin (P = 0.0011 for Balb/c and P = 0.0024 for B6), and reticulocytes (P<0.0001 for Balb/c and P = 0.0195 for B6), while there were no significant differences between vector and JAK2 WT recipients.
###end p 108
###begin p 109
(D) Reticulocyte stains of peripheral blood from recipients of BM transduced with JAK2 WT (left) or JAK2 V617F (right).
###end p 109
###begin p 110
(E-F): Erythrocyte survival curves (E) and red cell mass determination (F) for the three groups (Balb/c background).
###end p 110
###begin p 111
###xml 130 131 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 145 146 145 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 180 181 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
The red cell mass of JAK2 V617F recipients was significantly greater than that of recipients of vector- or JAK2 WT-transduced BM (P = 0.0068 and P = 0.0009, respectively, unpaired t-test).
###end p 111
###begin p 112
(G) Plasma Epo levels for the three groups (B6 background).
###end p 112
###begin p 113
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
The mean Epo level (bar) of JAK2 V617F recipients was significantly lower than that of recipients of vector- or JAK2 WT-transduced BM (P = 0.0048 and P = 0.0151, respectively, unpaired t-test).
###end p 113
###begin p 114
(H) Number of CFU-E colonies from normal BM (green) or spleen of JAK2 V617F recipients (red), expressed as percent of maximal colony number (Balb/c background).
###end p 114
###begin p 115
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Data for JAK2 WT recipients were similar to normal mice (data not shown).
###end p 115
###begin p 116
All studies were carried out between 6 and 10 weeks post-transplantation.
###end p 116
###begin title 117
Effect of JAK2 V617F on leukocyte and platelet counts.
###end title 117
###begin p 118
###xml 95 103 95 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000018-g001">Figure 1</xref>
(A) Peripheral blood leukocyte counts for the three cohorts in Balb/c and B6 backgrounds as in Figure 1.
###end p 118
###begin p 119
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
The difference in leukocyte counts between JAK2 V617F and JAK2 WT recipients was significant for the Balb/c cohort (P = 0.0039) but not for B6 (P = 0.0542, unpaired t-test).
###end p 119
###begin p 120
The hatched portion of the histogram represents the percentage of the total leukocyte count comprised by neutrophils.
###end p 120
###begin p 121
###xml 87 91 <span type="species:ncbi:10090">mice</span>
(B) Wright-Giemsa-stained cytospins of peripheral blood leukocytes from representative mice with BCR-ABL-induced CML-like MPD (left) or JAK2 V617F-induced PV-like MPD (right).
###end p 121
###begin p 122
Note the predominance of mature neutrophils and lack of immature myeloid elements (myelocytes and promyelocytes) in the JAK2 V617F recipient.
###end p 122
###begin p 123
(C) Platelet counts for the groups in (A).
###end p 123
###begin p 124
There was no significant difference in platelet counts between the three cohorts in either stain.
###end p 124
###begin p 125
###xml 178 182 <span type="species:ncbi:10090">mice</span>
(D) GFP fluorescence (left panels) and phase contrast images (right panels) of purified megakaryocytes from recipients of JAK2 V617F-transduced BM (top panels) or normal control mice (bottom panels).
###end p 125
###begin p 126
Note the GFP fluorescence in the majority of megakaryocytes from JAK2 V617F recipients.
###end p 126
###begin p 127
(E) Tail bleeding time (Balb/c cohort) for the three groups.
###end p 127
###begin p 128
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 137 138 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
The mean bleeding time (bar) of JAK2 V617F recipients was significantly longer than that of vector or JAK2 WT recipients (P = 0.0328 and P = 0.0002, respectively, unpaired t-test).
###end p 128
###begin title 129
Histopathological characterization of the MPD induced by JAK2 V617F.
###end title 129
###begin p 130
(A-C): Hematoxylin and eosin stains (magnification 500x) of BM (A), spleen (B), and liver (C) from representative polycythemic recipients of JAK2 V617F-transduced BM.
###end p 130
###begin p 131
In the spleen, a lymphoid follicle (f) and an area of erythroid hyperplasia (e) are indicated.
###end p 131
###begin p 132
The same tissues from recipients of JAK2 WT-transduced BM showed no pathological changes compared with normal controls (data not shown).
###end p 132
###begin p 133
###xml 190 194 <span type="species:ncbi:10090">mice</span>
(D) Wright-Giemsa stains (top panels) and acetylcholinesterase stains (bottom panels) of purified megakaryocytes from recipients of JAK2 V617F-transduced BM (right panels) or normal control mice (left panels).
###end p 133
###begin p 134
Note the preponderance of small megakaryocytes from JAK2 V617F recipients, some of which are undergoing proplatelet formation (arrowheads), accompanied by abnormal mitoses with low apparent ploidy (insert).
###end p 134
###begin p 135
(E) Flow cytometric analysis of BM and spleen from a representative recipient of JAK2 V617F-transduced BM, stained with the indicated hematopoietic lineage antigens.
###end p 135
###begin p 136
###xml 59 78 <span type="species:ncbi:35277">retroviral provirus</span>
The mean fluorescence intensity of GFP expressed from JAK2 retroviral provirus was reproducibly and significantly lower than the GFP fluorescence of a comparable BCR-ABL retrovirus (data not shown).
###end p 136
###begin p 137
###xml 21 25 21 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/lo</sup>
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Note the shift of GFP+/lo erythropoiesis (TER-119+) from BM to spleen and the expression of GFP in low abundance CD41+ megakaryocytes.
###end p 137
###begin p 138
###xml 62 66 62 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Socolovsky1">[47]</xref>
(F) Flow cytometric assessment of erythrocyte differentiation [47], assessed by expression of transferrin receptor (CD71) and TER-119 in splenocytes of recipients of JAK2 WT-transduced (top) and JAK2 V617F-transduced (bottom) BM.
###end p 138
###begin p 139
###xml 48 52 48 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/lo</sup>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Note the increased (3.5-fold) population of CD71+/loTER-119+ erythroblasts in JAK2 V617F recipients.
###end p 139
###begin title 140
Constitutive activation of signaling pathways by JAK2 V617F.
###end title 140
###begin p 141
###xml 91 95 <span type="species:ncbi:10090">mice</span>
(A-B): Western blot analysis of primary myeloerythroid cell extracts from control (normal) mice and recipients of JAK2 WT- and JAK2 V617F-transduced BM.
###end p 141
###begin p 142
(A) Activated JAK2 (anti-pY1007/10008, top panel) and total JAK2 (middle panel) blots.
###end p 142
###begin p 143
Note that JAK2 V617F is modestly overexpressed and constitutively active.
###end p 143
###begin p 144
Anti-actin immunoblot demonstrating equivalent protein loading is at the bottom.
###end p 144
###begin p 145
###xml 81 82 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
(B) Constitutive activation of Stat5, Gab2, and ERK, with overexpression of Bcl-XL in spleen cells from JAK2 V617F recipients.
###end p 145
###begin p 146
###xml 42 46 <span type="species:ncbi:10090">mice</span>
Primary myeloerythroid cell extracts from mice in (A) were immunoblotted with the indicated antibodies against total or phosphorylated Stat5, Gab2, ERK, and against Bcl-X.
###end p 146
###begin p 147
(C) Oligo- to polyclonal MPD in recipients of JAK2 V617F-transduced BM.
###end p 147
###begin p 148
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GFP</italic>
Genomic DNA from spleens of individual JAK2 V617F recipients sacrificed at the indicated times post-transplant were analyzed with a radioactive GFP probe that detects a distinct band from each proviral integration event.
###end p 148
###begin p 149
###xml 138 143 <span type="species:ncbi:10090">mouse</span>
For comparison, DNAs from control Ba/F3 cell lines each containing a single provirus (Con1 and Con2) and spleen DNA from a representative mouse with BCR-ABL-induced CML-like MPD are included at left, along with DNA size markers in kb.
###end p 149
###begin title 150
Evolution of JAK2 V617F-induced polycythemia to "spent" phase with myelofibrosis.
###end title 150
###begin p 151
###xml 125 126 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
(A) Box-style plots of hematocrit (red squares, left axis) and reticulocyte counts (blue triangles, right axis) in a cohort (n = 12) of Balb/c recipients of syngeneic JAK2 V617F-transduced BM, followed for over eight months after transplantation.
###end p 151
###begin p 152
Similar data were observed for a B6 cohort (data not shown).
###end p 152
###begin p 153
(B) Increasing fibrosis (demonstrated by reticulin staining) in spleen (left panels) and BM (right panels) of representative JAK2 V617F recipients at about 3 months (middle panels) and 7 months (bottom panels) after transplantation.
###end p 153
###begin p 154
Note the marked increase in reticulin staining at 7 months in the JAK2 V617F recipients, but not in recipients of JAK2 WT-transduced BM (top panels).
###end p 154
###begin p 155
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 358 359 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
(C): Efficient transfer of the PV-like MPD by transplantation of BM from primary mice sacrificed either in the early, polycythemic phase (left, n = 3, sacrificed 72-167 days post-transplant) or the late, myelofibrotic phase (right, n = 2, sacrificed 208 days post-transplant), to lethally irradiated syngeneic secondary recipients (n = 6 for early phase and n = 4 for late phase).
###end p 155
###begin p 156
The graphs depict mean hematocrit (black, left axis), reticulocyte count (white, right axis) and peripheral blood leukocyte count (grey, right axis) of the donors at the time of sacrifice, and of the recipients at day 30-70 post-transplant.
###end p 156
###begin p 157
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 174 175 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
For transplants performed in the late phase of the disease, the hematocrit and reticulocyte counts of recipients were significantly higher than of the donors (P = 0.0407 and P = 0.0337, respectively, unpaired t-test), while there was no significant difference between donors and recipients transplanted in the early phase.
###end p 157
###begin title 158
Polycythemia induced by JAK2 V617F is independent of Src kinases.
###end title 158
###begin p 159
###xml 220 223 220 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 223 226 223 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 226 229 226 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hck</italic>
###xml 229 232 229 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 232 235 232 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fgr</italic>
###xml 235 238 235 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 170 176 <span type="species:ncbi:10090">murine</span>
(A-C): Hematocrit (A), blood hemoglobin (B), and reticulocyte counts (C) from normal (-) B6 mice (green), B6 recipients of B6 WT BM transduced with retrovirus expressing murine JAK2 WT (blue) or JAK2 V617F (red), and B6 Lyn-/-Hck-/-Fgr-/- BM transduced with retrovirus expressing JAK2 V617F (orange).
###end p 159
###begin p 160
###xml 59 62 59 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 62 65 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 65 68 65 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hck</italic>
###xml 68 71 68 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fgr</italic>
###xml 74 77 74 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 175 176 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 340 343 340 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 343 346 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 346 349 346 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hck</italic>
###xml 349 352 349 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 352 355 352 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fgr</italic>
###xml 355 358 355 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
The difference between recipients of JAK2 V617F-transduced Lyn-/-Hck-/-Fgr-/- BM and recipients of JAK2 WT-transduced WT BM was significant (unpaired t-tests) for hematocrit (P = 0.0009), hemoglobin (P = 0.0007), and reticulocytes (P = 0.0068), while the corresponding differences between recipients of JAK2 V617F-transduced BM from WT and Lyn-/-Hck-/-Fgr-/- donors were not significant.
###end p 160
###begin p 161
###xml 271 274 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 274 277 274 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 277 280 277 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hck</italic>
###xml 280 283 280 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 283 286 283 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fgr</italic>
###xml 286 289 286 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
(D) Western blot analysis of extracts of primary myeloerythroid cells from individual normal (lanes 1-3) B6 mice, recipients of WT BM transduced with JAK2 WT retrovirus (lanes 4-5), recipients of WT BM transduced with JAK2 V617F retrovirus (lanes 6-9), and recipients of Lyn-/-Hck-/-Fgr-/- BM transduced with JAK2 V617F retrovirus (lanes 10-14).
###end p 161
###begin p 162
The membrane was immunoblotted with antibody recognizing the phosphorylated activation loop tyrosine (Y146 homolog) of c-Src, Lyn, Hck, Fyn, Lck, and Yes (top panel), and subsequently blotted with antibody recognizing total c-Src, Fyn, Yes, and Fgr (bottom panel).
###end p 162
###begin title 163
Polycythemia and reticulocytosis induced by JAK2 V617F responds to kinase inhibitor therapy.
###end title 163
###begin p 164
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 175 176 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 195 196 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
(A) Hematocrit (left panel) and reticulocyte counts (right panel) of cohorts of mice treated with twice daily oral gavage with 100 mg/kg imatinib (n = 3), 10 mg/kg dasatinib (n = 4), or vehicle (n = 2), determined before initiation of therapy (white bars, "pre") or after 2 weeks of treatment (black bars, "post").
###end p 164
###begin p 165
###xml 100 101 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
The hematocrit and reticulocyte count were significantly decreased in response to imatinib therapy (P = 0.0267 and P = 0.0053, respectively, unpaired t-test), while imatinib had no effect on these parameters in normal mice (data not shown).
###end p 165
###begin p 166
(B) Inhibition of Ba/F3 parental cells grown in IL-3 (green squares) or Ba/F3 cells expressing BCR-ABL (magenta triangles) or JAK2 V617F (red circles) grown without IL-3 by JAK Inhibitor I (left) or AG-490 (right).
###end p 166
###begin p 167
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000018-Xie1">[48]</xref>
Note that both JAK Inhibitor I and AG-490 inhibit IL-3-dependent proliferation of parental Ba/F3 cells, but only AG-490 inhibits the growth of BCR-ABL-expressing cells, as previously reported [48].
###end p 167
###begin p 168
###xml 150 151 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 169 170 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
(C) Hematocrit (left panel) and reticulocyte counts (right panel) of mice treated with continuous parenteral administration of 300 microg/day AG-490 (n = 3) or vehicle (n = 2), determined before initiation of therapy (white bars), or after 2 weeks of treatment (black bars).
###end p 168
###begin p 169
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 113 114 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 148 149 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
The hematocrit and reticulocyte count were significantly decreased in response to AG-490 therapy (P = 0.0134 and P = 0.0374, respectively, unpaired t-test).
###end p 169
###begin p 170
There was no significant effect of AG-490 on the hematocrit or reticulocyte count of recipients of JAK2 WT-transduced BM (data not shown).
###end p 170
###begin p 171
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 171
###begin p 172
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Supported by NIH grants CA90576 and HL56949 (to R.A.V.), T32CA009429 (to V.Z.) and CA11419 (to S.L.), and by a SCOR grant from the Leukemia and Lymphoma Society (to R.A.V.).
###end p 172

